These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38708616)
41. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients. Allan B; Davis J; Perez E; Lew J; Sola J Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065 [TBL] [Abstract][Full Text] [Related]
42. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Chang JS; Chen LT; Shan YS; Chu PY; Tsai CR; Tsai HJ Sci Rep; 2021 Apr; 11(1):7881. PubMed ID: 33846396 [TBL] [Abstract][Full Text] [Related]
43. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis. Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563 [TBL] [Abstract][Full Text] [Related]
44. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. Tsai HJ; Wu CC; Tsai CR; Lin SF; Chen LT; Chang JS PLoS One; 2013; 8(4):e62487. PubMed ID: 23614051 [TBL] [Abstract][Full Text] [Related]
45. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241 [TBL] [Abstract][Full Text] [Related]
46. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Sonbol MB; Mazza GL; Mi L; Oliver T; Starr J; Gudmundsdottir H; Cleary SP; Hobday T; Halfdanarson TR Oncologist; 2022 Jul; 27(7):573-578. PubMed ID: 35348774 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study. Tian FX; Cai YQ; Zhuang LP; Chen MF; Xiu ZB; Zhang Y; Liu H; Liu ZH; Liu GP; Zeng C; Lin FL; Liu J; Huang ST; Zhang LZ; Lin HY Cancer Med; 2018 Nov; 7(11):5359-5369. PubMed ID: 30311450 [TBL] [Abstract][Full Text] [Related]
48. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015. Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325 [TBL] [Abstract][Full Text] [Related]
49. Endoscopic and surgical treatment of T1N0M0 colorectal neuroendocrine tumors: a population-based comparative study. Zhu H; Zhao S; Zhang C; Ji K; Wu W; Yin L; Yan H; Zhou J; Tang R; Miao L Surg Endosc; 2022 Apr; 36(4):2488-2498. PubMed ID: 33987767 [TBL] [Abstract][Full Text] [Related]
50. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. Liu M; Wei L; Liu W; Chen S; Guan M; Zhang Y; Guo Z; Liu R; Xie P Front Oncol; 2023; 13():1079575. PubMed ID: 36776304 [TBL] [Abstract][Full Text] [Related]
51. Association of race and health care system with disease stage and survival in veterans with larynx cancer. Voora RS; Kotha NV; Kumar A; Qiao EM; Qian AS; Panuganti BA; Banegas MP; Weissbrod PA; Stewart TF; Rose BS; Orosco RK Cancer; 2021 Aug; 127(15):2705-2713. PubMed ID: 33799314 [TBL] [Abstract][Full Text] [Related]
52. Survival Profile and Prognostic Factors for Appendiceal Mixed Neuroendocrine Non-neuroendocrine Neoplasms: A SEER Population-Based Study. Zheng M; Li T; Li Y; Zhang T; Zhang L; Ma W; Zhou L Front Oncol; 2020; 10():1660. PubMed ID: 32903647 [TBL] [Abstract][Full Text] [Related]
53. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Das S; Dasari A Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003 [TBL] [Abstract][Full Text] [Related]
54. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
55. The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. Liu X; Chen B; Chen J; Su Z; Sun S J Endocrinol Invest; 2023 Jul; 46(7):1373-1384. PubMed ID: 36522587 [TBL] [Abstract][Full Text] [Related]
56. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409 [TBL] [Abstract][Full Text] [Related]
57. Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years. Wijayabahu AT; Shiels MS; Arend RC; Clarke MA Am J Obstet Gynecol; 2024 Nov; 231(5):526.e1-526.e22. PubMed ID: 38925206 [TBL] [Abstract][Full Text] [Related]
58. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. Gittleman H; Ostrom QT; Farah PD; Ondracek A; Chen Y; Wolinsky Y; Kruchko C; Singer J; Kshettry VR; Laws ER; Sloan AE; Selman WR; Barnholtz-Sloan JS J Neurosurg; 2014 Sep; 121(3):527-35. PubMed ID: 24926650 [TBL] [Abstract][Full Text] [Related]
59. Primary cerebral lymphoma' characteristics, incidence, survival, and causes of death in the United States. Ghozy S; Dibas M; Afifi AM; Hashim MA; Abbas AS; Abdel-Daim MM; Phan K J Neurol Sci; 2020 Aug; 415():116890. PubMed ID: 32428760 [TBL] [Abstract][Full Text] [Related]
60. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms. Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]